ArticleCPT: pharmacometrics & systems pharmacology2020

Tumor Time-Course Predicts Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow-Up Time.

Ida Netterberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.